Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study
Metrics: PDF 1054 views | HTML 1819 views | ?
Taku Fujimura1, Yota Sato1, Kayo Tanita1, Yumi Kambayashi1, Atsushi Otsuka2, Yasuhiro Fujisawa3, Koji Yoshino4, Shigeto Matsushita5, Takeru Funakoshi6, Hiroo Hata7, Yuki Yamamoto8, Hiroshi Uchi9, Yumi Nonomura2, Ryota Tanaka3, Megumi Aoki5, Keisuke Imafuku7, Hisako Okuhira8, Sadanori Furudate1, Takanori Hidaka1 and Setsuya Aiba1
1Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan
2Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
3Department of Dermatology, Faculty of University of Tsukuba, Tsukuba, Japan
4Department of Dermatology, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Tokyo, Japan
5Department of Dermato-Oncology/Dermatology, National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan
6Department of Dermatology, Keio University School of Medicine, Tokyo, Japan
7Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
8Department of Dermatology, Wakayama Medical University, Wakayama, Japan
9Department of Dermatology, Kyushu University Graduate School of Medicine, Fukuoka, Japan
Taku Fujimura, email: email@example.com
Keywords: sCD163; CXCL5; TAMs; melanoma; POSTN
Received: September 01, 2017 Accepted: February 10, 2018 Epub: February 15, 2018 Published: March 20, 2018
Antibodies against PD-1, such as nivolumab and pembrolizumab, are widely used in the treatment of various cancers including advanced melanoma. The anti-PD-1 Ab significantly prolongs survival in patients with metastatic melanoma, and its administration in combination with local or systemic therapy may also lead to improved outcomes. Although anti-PD-1 Ab-based combined therapy might be effective for the treatment of advanced melanoma, the associated risk of irAEs is an important consideration. Therefore, being able to predict irAEs is of great interest to oncologists. The purpose of this study was to evaluate the value of using serum levels of sCD163 and CXCL5 to predict irAEs in patients with advanced melanoma who were administered nivolumab. To this end, we analyzed these serum levels in 46 cases of advanced melanoma treated with nivolumab. In addition, the tumor stroma was evaluated by immunohistochemistry and immunofluorescence. We measured the serum levels of sCD163 and CXCL5 on day 0 (immediately before nivolumab administration) and day 42. The serum absolute levels of sCD163 were significantly increased in patients who developed AEs (p = 0.0018). Although there was no significant difference in serum levels of CXCL5, the absolute value of CXCL5 could at least be a supportive marker for the increased absolute levels of serum sCD163. This study suggests that sCD163 and CXCL5 may serve as possible prognostic biomarkers for irAEs in patients with advanced melanoma treated with nivolumab.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.